Effective new target for mood-boosting brain stimulation found
for medical reasons to pinpoint the origin of their seizures. Many of those patients also suffered from depression, which is often seen in people with epilepsy. With the patients’ consent, Chang’s team took advantage of those electrodes to deliver small electrical pulses to areas of the brain thought to be involved in regulating mood.
Previous studies have explored deep brain stimulation (DBS) for mood disorders, but its success depends critically on target selection. Targets in other moodrelated areas deep in the brain hadn’t always led to reliable improvements.
In the new study, the researchers focused their attention and the electrical stimulation on the OFC. The OFC is a key hub for mood-related circuitry. But it’s also widely regarded as one of the least wellunderstood brain regions.
“Although OFC is a more superficial target, it shares rich interconnections with several brain regions implicated in emotion processing,” Sellers said. That made this relatively small brain area an attractive target for therapeutic stimulation.
The researchers used the implanted electrodes to stimulate OFC and other brain regions while collecting verbal mood reports and questionnaire scores. Those studies found that unilateral stimulation of the lateral OFC produced acute, dose-dependent mood-state improvement in subjects with moderate-to-severe baseline depression. The changes in brain activity the researchers observed after stimulation closely resembled those seen when people are in a good mood.
The findings show that mood can be immediately improved by electrical stimulation of a relatively small area of brain, the researchers said. They also add to evidence that mood disorders are the result of dysfunction in brain circuits.
The researchers say that plenty of work remains before DBS could enter routine clinical practice. Chang’s team is currently exploring whether stimulation of OFC produces durable improvement in mood over longer periods of time. They also hope to develop a medical device for patients with treatment-resistant mood disorders that can monitor brain activity in OFC and stimulate only when needed to keep that activity within a healthy range.
“Ultimately, it would be ideal if activity in mood-related brain circuits could be normalized indefinitely without patients needing to do anything,” Rao said.